Literature DB >> 17942915

Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.

Taro Takami1, Pal Kaposi-Novak, Koichi Uchida, Luis E Gomez-Quiroz, Elizabeth A Conner, Valentina M Factor, Snorri S Thorgeirsson.   

Abstract

Hepatocyte growth factor (HGF) has been reported to have both positive and negative effects on carcinogenesis. Here, we show that the loss of c-Met signaling in hepatocytes enhanced rather than suppressed the early stages of chemical hepatocarcinogenesis. c-Met conditional knockout mice (c-metfl/fl, AlbCre+/-; MetLivKO) treated with N-nitrosodiethylamine developed significantly more and bigger tumors and with a shorter latency compared with control (w/w, AlbCre+/-; Cre-Ctrl) mice. Accelerated tumor development was associated with increased rate of cell proliferation and prolonged activation of epidermal growth factor receptor (EGFR) signaling. MetLivKO livers treated with N-nitrosodiethylamine also displayed elevated lipid peroxidation, decreased ratio of reduced glutathione to oxidized glutathione, and up-regulation of superoxide dismutase 1 and heat shock protein 70, all consistent with increased oxidative stress. Likewise, gene expression profiling done at 3 and 5 months after N-nitrosodiethylamine treatment revealed up-regulation of genes associated with cell proliferation and stress responses in c-Met mutant livers. The negative effects of c-Met deficiency were reversed by chronic p.o. administration of antioxidant N-acetyl-L-cysteine. N-acetyl-L-cysteine blocked the EGFR activation and reduced the N-nitrosodiethylamine-initiated hepatocarcinogenesis to the levels of Cre-Ctrl mice. These results argue that intact HGF/c-Met signaling is essential for maintaining normal redox homeostasis in the liver and has tumor suppressor effect(s) during the early stages of N-nitrosodiethylamine-induced hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942915     DOI: 10.1158/0008-5472.CAN-07-1905

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.

Authors:  Xu-Feng Zhang; Xinping Tan; Gang Zeng; Amalea Misse; Sucha Singh; Youngsoo Kim; James E Klaunig; Satdarshan P S Monga
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Authors:  Luis E Gomez-Quiroz; Daekwan Seo; Yun-Han Lee; Mitsuteru Kitade; Timo Gaiser; Matthew Gillen; Seung-Bum Lee; Ma Concepcion Gutierrez-Ruiz; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson; Jens U Marquardt
Journal:  Toxicology       Date:  2016-07-06       Impact factor: 4.221

3.  Biological roles of hepatocyte growth factor-Met signaling from genetically modified animals.

Authors:  Takashi Kato
Journal:  Biomed Rep       Date:  2017-10-18

Review 4.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Authors:  Vincent W Keng; Augusto Villanueva; Derek Y Chiang; Adam J Dupuy; Barbara J Ryan; Ilze Matise; Kevin A T Silverstein; Aaron Sarver; Timothy K Starr; Keiko Akagi; Lino Tessarollo; Lara S Collier; Scott Powers; Scott W Lowe; Nancy A Jenkins; Neal G Copeland; Josep M Llovet; David A Largaespada
Journal:  Nat Biotechnol       Date:  2009-02-22       Impact factor: 54.908

6.  Met receptor tyrosine kinase degradation is altered in response to the leucine-rich repeat of the Listeria invasion protein internalin B.

Authors:  Xiu Gao; Marta Lorinczi; Kristen S Hill; Natasha C Brooks; Hatem Dokainish; Keith Ireton; Lisa A Elferink
Journal:  J Biol Chem       Date:  2008-11-06       Impact factor: 5.157

7.  Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors:  Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

8.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.

Authors:  Liem M Phan; Enrique Fuentes-Mattei; Weixin Wu; Guermarie Velazquez-Torres; Kanishka Sircar; Christopher G Wood; Tao Hai; Camilo Jimenez; Gilbert J Cote; Levent Ozsari; Marie-Claude Hofmann; Siyuan Zheng; Roeland Verhaak; Lance Pagliaro; Maria Angelica Cortez; Mong-Hong Lee; Sai-Ching J Yeung; Mouhammed Amir Habra
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

Review 9.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

10.  Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Authors:  Luis E Gómez-Quiroz; Valentina M Factor; Pal Kaposi-Novak; Cedric Coulouarn; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  J Biol Chem       Date:  2008-03-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.